Weekly Spotlight - 21.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

Dapirolizumab Pegol Phase 3 Data Shows Significant Reduction in Lupus Disease Activity

A new drug, dapirolizumab pegol, has shown promising results in a Phase 3 study presented at the American College of Rheumatology. The study found that the drug significantly reduced disease activity in patients with SLE, offering potential new treatment options for those suffering from this condition.

Aurinia Highlights Early Lupus Nephritis Detection and LUPKYNIS® Efficacy at ACR Convergence 2024

Aurinia presented new data at the American College of Rheumatology Convergence 2024, highlighting the importance of early detection and treatment of Lupus Nephritis, a common complication of SLE.The data also showed the effectiveness of LUPKYNIS in managing Lupus Nephritis.

Adicet Bio Doses First Lupus Nephritis Patient in Phase 1 Trial of ADI-001 for Autoimmune Diseases

Adicet Bio has started a Phase 1 clinical trial for ADI-001, a new treatment for autoimmune diseases, including SLE. The first patient with lupus nephritis, a common complication of SLE, has been dosed in the trial to evaluate the treatment's safety and efficacy.

Addressing Economic Insecurities May Improve Patient Outcomes in Lupus

The article discusses how addressing economic insecurities can improve the health outcomes of patients with SLE. It highlights that financial stress can worsen SLE symptoms and suggests that reducing economic burdens could lead to better patient-reported health outcomes.

Genetic and Lifestyle Models Accurately Predict Lupus Outcomes in Various Scenarios

Researchers have developed models that use genetics and lifestyle factors to predict the onset of SLE. These models perform well in various scenarios, offering potential for early diagnosis and personalized treatment plans for individuals at risk of developing SLE.